Introduction {#Sec1}
============

The majority of the central nervous system (CNS) lymphomas are due to the spread of a systemic lymphoma to the CNS \[[@CR1], [@CR2]\]. Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) that involves the brain, leptomeninges, intraocular structures, or spinal cord in the absence of systemic disease. It occurs in both immunocompromised and immunocompetent patients and accounts for 2.7% of all malignant diseases of the central nervous system \[[@CR3]\]. The incidence of PCNSL has increased during the last three decades, and it occurs at a younger age in the immunocompromised patients.

According to World Health Organization classification \[[@CR4]\], the majority of PCNSL are diffuse large B-cell lymphoma. T-cell (T-PCNSL), low grade B-cell lymphomas, and anaplastic large cell lymphoma of the CNS are extremely rare \[[@CR5], [@CR6]\]. The PCNSL in human immunodeficiency virus positive patients is almost always associated with the Epstein--Barr virus (EBV), while the association of EBV in immunocompetent patients is rare \[[@CR7]\].

The majority of PCNSL presents as a space-occupying lesion within the brain parenchyma and periventricular regions. Primary dural CNS lymphomas are extremely rare. The majority of them are low grade NHL, with marginal zone B-cell lymphoma being the most common. There are only a handful of case reports and a small case series which describe the dural involvement \[[@CR8]--[@CR10]\]. In the present study, we describe the clinical, histopathological, immunohistochemical, cytogenetic, and molecular findings of a case of primary extranodal marginal zone lymphoma involving the dura with extension to the brain parenchyma in an immunocompetent patient. This is the first report of a primary dural marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type that has shown a molecular rearrangement of t(14;18)(q32;q21) involving the MALT1gene.

Material and methods {#Sec2}
====================

All available routine hematoxylin and eosin, immunohistochemical, and in situ hybridization slides of formalin-fixed paraffin-embedded tissue from a diagnostic biopsy of the patient were reviewed. Working antibody source, clone, and dilution are listed in Table [1](#Tab1){ref-type="table"}. Staining was performed on an automated immunostainer (Ventana Medical Systems, Tuscon, AZ and Dako, Carpentaria, CA, USA). For in situ hybridization (ISH), slides were deparaffinized and antigen retrieval was performed by a Ventana's proprietary protease-1 treatment. Subsequently, the slides were incubated with undiluted Kappa, Lambda, and EBV probe solutions from Ventana. Table 1Panel of antibodiesAntibody toCloneCompanyDilutionCD20L26Dako^a^1:500CD79aJCB117Dako1:80CD3F7.2.38DakoNeatCD5SP19Ventana^b^NeatCyclin D1SP4Ventana1:100CD211F8Dako1:80Ig GA57HDako1:200Ig MR1/69Dako1:200CD1056C6VentanaNeat^a^Dako, Carpenteria, CA, USA^b^Ventana, Tucson, AZ, USA

Fluorescent in situ hybridization {#Sec3}
---------------------------------

Fluorescence in situ hybridization (FISH) was performed on 4--5-μm unstained paraffin-embedded tissue sections using the LSI immunoglobulin heavy-chain (IgH)/MALT1 dual-fusion translocation probe and the LSI BCL6 (3q27) dual-color break-apart probe obtained from Vysis/Abbott, Inc. (Downer's Grove, IL, USA). Prior to hybridization, the slides were pretreated by utilizing the VP 2000 automated slide processor (Vysis/Abbott, Inc.) following a modified version of the manufacturer's recommended protocol. Codenaturation of the DNA probe and the tissue DNA was performed on a HYBrite^™^ instrument (Vysis/Abbott, Inc., IL, USA) at 80°C for 5 min, followed by an overnight hybridization at 37°C, postwashed in 2× SSC/0.3% NP-40 at 73°C for 2 min, and counterstained with 4′,6-diamidino-2-phenylindole II.

Molecular diagnostics {#Sec4}
---------------------

Immunoglobulin heavy-chain gene rearrangements were analyzed by using the InVivoScribe IgH framework III/heavy-chain joining (JH) assay, according to the manufacturer's protocol (InVivoScribe Technologies, San Diego, CA, USA). Framework II/JH segments were amplified using the forward (5′ TGG RTC CGM CAG SCY YCN GG 3′) and reverse (5′ 6-FAM ACC TGA GGA GAC GGT GAC C 3′) primers as previously described \[[@CR11]\]. Polymerase chain reaction (PCR) products were analyzed using a capillary electrophoresis as described previously \[[@CR12]\].

Case report {#Sec5}
===========

The patient was a 59-year-old gentleman, who presented with speech difficulties, right-sided numbness, and episodes of unusual smell for 8 months. He did not have a history of headache, seizures, and inflammatory conditions. A magnetic resonance imaging scan showed a heterogeneously enhancing 22-mm tumor located in the left posterior temporal lobe abutting the dura. Subsequently, he underwent left temporal craniotomy and microsurgical resection of the tumor. The patient underwent computed tomography scans of the chest, abdomen, and pelvis (staging), with normal findings. Bone marrow aspiration and biopsy examinations did not reveal any evidence of lymphoma. A work-up for monoclonal gammopathy including serum protein electrophoresis and serum level of immunoglobulin A, G, and M showed normal results.

Results {#Sec6}
=======

The histopathology of the tumor showed a prominent lymphoplasmacytic infiltration in the brain parenchyma and the overlying fibrous (dura) tissue. The tumor showed a characteristic, angiocentric pattern, forming cuffs of tumor cells around the cerebral blood vessels (Virchow--Robin space; Fig. [1](#Fig1){ref-type="fig"}A,B). Most of the lymphocytes were small with condensed chromatin in a round to slightly irregular nucleus and a scant to moderate amount of pale cytoplasm. A prominent plasma cell population was present. Reactive lymphoid follicles were not identified. Fig. 1Morphologic, immunohistochemical, Ig light chain expression and FISH assay of the PCNS MALT lymphoma. **A** and **B** Histopathology of the lymphoma showing a prominent lymphoplasmacytic infiltration with a characteristic perivascular pattern (hematoxylin--eosin, original magnification, ×100 and ×400). **C** and **D** Many of the lymphoma cells were positive for CD 20 and CD 79a (immunohistochemistry ×100). **E** In situ hybridization showing the tumor cells are kappa light chain restricted (×100). **F** In situ hybridization showing the tumor cells are lambda light chain negative (×100). **G** FISH analysis showing the interphase cells with IGH/MALT1 rearrangement indicated by two fusion signals (juxtaposed *green* and *red* signal). The normal IgH and MALT1 loci are represented by the single *red* and single *green* signals respectively (×100)

Immunohistochemical studies showed that the tumor cells were positive for B-cells markers (cluster of differentiation (CD) 20, CD79a; Fig. [1](#Fig1){ref-type="fig"}C,D). The neoplastic plasma cells were monoclonal for Ig G and kappa light chain (Fig. [1](#Fig1){ref-type="fig"}E), and negative for lambda light chain (Fig. [1](#Fig1){ref-type="fig"}F). The tumor cells were immunonegative for CD3, CD5, cyclin D1, CD21, CD23, CD10, and Ig M. EBV testing by ISH (EBV-encoded small RNA) was negative. The FISH study for MALT1 translocations showed a rearrangement of the MALT1 region at 18q21 in 30% of the interphase cells. Subsequent studies showed fusion of IgH/MALT1 in 74% of the cells (Fig. [1](#Fig1){ref-type="fig"}G). Additional studies for trisomy 3 and 7 were negative. The molecular study for IgH rearrangement by PCR showed a single peak indicating clonal immunoglobulin heavy-chain gene rearrangement using the primers for heavy-chain variable (VH; framework II) and JH regions (Fig. [2](#Fig2){ref-type="fig"}). The tumor was negative for clonal IgH gene by PCR using the primers to VH framework III and JH regions. The staging evaluation was negative for systemic involvement by lymphoma. Fig. 2Immunoglobulin heavy-chain gene rearrangement study---PCR product analyzed by capillary electrophoresis showing a clonal rearrangement. *X axis* length of amplicon, *Y axis* intensity of signal

Discussion {#Sec7}
==========

Isaacson and Wright were the first to describe the marginal zone B-cell lymphoma (MZL) in mucosa-associated lymphoid tissue of the gastrointestinal tract in 1983 \[[@CR13]\]. Depending on the site of involvement, the MZL is classified into three subtypes: (1) splenic MZL, (2) nodal MZL, and (3) extranodal MZL of the mucosa-associated lymphoid tissues type \[[@CR14], [@CR15]\].

Among the MALT lymphomas, the gastrointestinal tract and lungs are the most common sites \[[@CR16]\]. It is also recognized in salivary glands, skin, thyroid, lung, ocular adnexa, liver, CNS, and breast \[[@CR17]\]. MALT lymphoma of the CNS is extremely rare. Dural MALT lymphoma is the most common site of involvement in the CNS with a rare occurrence in the lateral ventricle \[[@CR18], [@CR19]\].

To date, 39 cases of primary dural MALT lymphomas have been reported in the literature (Table [2](#Tab2){ref-type="table"}). They usually occur in the middle-aged to elderly women and present with headache, seizures, and visual disturbance \[[@CR18]\]. Although CNS is devoid of mucosal tissue, it has been hypothesized that the meningothelial cells serve as a substitute for the mucosal surface in MALT lymphoma of the CNS \[[@CR20], [@CR21]\]. Table 2Clinicopathological features of the reported cases of primary central nervous system lymphoma of mucosa-associated lymphoid tissue typeCaseReferenceLocation of duraPresenting symptomsAge (years)SexPreexisting conditionTreatmentFISH studiesIgH studiesFollow up (months)Status1Kumar et al. \[[@CR21]\]Cavernous sinusNumbness and visual field defects40FNoneRTNDND63CR12Kumar et al. \[[@CR21]\]BiparietalSeizures62FNoneChemoNDMono22CR13Kumar et al. \[[@CR21]\]FrontalSeizures; numbness52FNoneRT and chemoNDMono7CR14Kumar et al. \[[@CR21]\]TentoriumHeadache, visual defect, numbness43FNoneRTNDNegative9CR15Kumar et a1. \[[@CR21]\]Falx cerebriSeizures57FNoneRTNDMono14CR16Kambham et al. \[[@CR26]\]TentoriumHearing loss, weakness39FNoneResectionNDMono48AWD7Kambham et al. \[[@CR26]\]FrontoparietalHeadache, visual defect, numbness62FNoneResection and RTNDNegative6AWD8Altundag et al. \[[@CR27]\]ParietalSeizures66FNoneResectionNDND12CR19Itoh et al. \[[@CR20]\]CerebellopontineTinnitus, headache28FSjogren\'s syndromeResectionNDND24CR110Sanjeevi et al. \[[@CR28]\]Cavernous sinusHeadache, visual defect46FGrave\'s diseaseResection and RTNDND15CR111Goetz et al. \[[@CR29]\]FrontoparietalHemiparesis64FNoneResection and RTNDND3CR112Bodi et al. \[[@CR30]\]FrontalSeizures, dizziness56FNoneResectionNDND18CR113Lehman et al. \[[@CR31]\]Falx cerebriSeizures, speech defect63FNoneRTNDND8AWD14Benouaich et al. \[[@CR32]\]FrontoparietalHeadache38FNoneRT and chemoNDND24CR115Benouaich et al. \[[@CR32]\]Temporal, parieto-occipitalHeadache45FNoneRT and chemoNDND12CR116Kelly et al. \[[@CR18]\]Choroid plexusHeadache, seizures53MNoneResection and RTNegativeND12CR117Tu et al. \[[@CR25]\]Falx cerebriNA56FNoneNot availableTri 3NegativeNANA18Tu et al. \[[@CR25]\]Frontal duraSeizures49MNoneChemoTri 3Negative90CR119Tu et al. \[[@CR25]\]Frontal duraSeizures66MNoneRTTri 3Negative13CR120Tu et al. \[[@CR25]\]Posterior fossaNA55FNoneNANDNegativeNANA21Tu et al. \[[@CR25]\]Middle cranial fossaNA45FNoneNANDNegativeNANA22Tu et al \[[@CR25]\]NANA68FNoneNATri 3NegativeNANA23Tu et al. \[[@CR25]\]SubduralNA29FNoneRTNegativeNegative36CR124Tu et al. \[[@CR25]\]FrontotemporalHeadache, drowsiness61FNoneNANegativeNegative21CR125Tu et al. \[[@CR25]\]OccipitalAtaxia62FNoneRTTri 3, 7, 12, 18Negative25CR126Tu et al. \[[@CR25]\]ParietalFacial drop, numbness, dysarthria47MNoneNANDNDNANA27Tu et al. \[[@CR25]\]FrontoparietalRight arm pain57FNoneRT and chemoNegativeNegative65CR128Tu et al. \[[@CR25]\]TentoriumVisual deficits70FNoneRTNegativeNegative45CR129Tu et al. \[[@CR25]\]FalxGait disturbance, visual deficits59FNoneRTNegativeNegative32CR130Tu et al. \[[@CR25]\]Suprasellar, sellaHeadache, visual deficits53FNoneRTNegativeNegative11CR131Tu et al. \[[@CR25]\]Falx tentoriumHeadache, ear pain48FNoneRT and chemoTri 3, 7, 12, 18Negative20CR132Iwamoto et al. \[[@CR33]\]TemporoparietalHeadache, facial weakness64FNoneResection and chemoNDND78CR133Iwamoto et al. \[[@CR33]\]FrontotemporalSeizures, visual defects33FNoneRT and chemoNDND84CR134Iwamoto et al. \[[@CR33]\]Tentorium, temporalHeadache, dizziness, numbness35MNoneRT and chemoNDND53CR135Iwamoto et al. \[[@CR33]\]TentoriumSeizures47MNoneRTNDND27CR136Iwamoto et al. \[[@CR33]\]Frontal, sphenoidalVisual deficits, paresthesias39FNoneRTNDND6CR137Iwamoto et al. \[[@CR33]\]ParietalSeizures49FNoneRTNDND7CR138Iwamoto et al. \[[@CR33]\]FrontalHeadache51FNoneRTNDND8CR139Iwamoto et al. \[[@CR33]\]FrontalHeadache, visual deficits50FNoneRTNDND5CR140Bhagavathi et al. \[present report\]TemporalAltered speech, numbness59MNoneRTt(14;18)(q32;q21)Mono1AWD*M* Male, *F* female *RT* radiotherapy, *chemo* chemotherapy, *ND* not done, *CR* complete remission, *AWD* alive with disease, *NA* not available, *FISH* fluorescent in situ hybridization, *IgH* immunoglobulin heavy-chain gene rearrangement, *mono* monoclonal

MALT lymphomas typically present as a local mass without bone marrow and lymph node involvement in contrast to nodal and splenic MZL. They arise from the marginal zone B-cells and show a spectrum of cellular constituents, from small lymphocytes to monocytoid B-cells to plasma cells. The lymphocytes express B-cell markers (CD19, CD20, and CD79a) and are negative for CD3, CD5, CD10, CD23, and cyclin D1.

In the present case, the morphological, immunohistochemical, and in situ hybridization studies showed that the lymphoma is a low grade MZL, with prominent plasma cell differentiation that is Ig G and kappa light chain restricted. The tumor infiltrated into the underlying brain parenchyma in a perivascular pattern. Small lymphocytic lymphoma/chronic lymphocytic leukemia and mantle-cell lymphomas were excluded by the negative immunostaining for CD5, CD23, and cyclin D1. Follicular lymphoma and lymphoplasmacytic lymphoma were excluded by the morphology, negative CD10, normal serum Ig M, and negative bone marrow examination.

Infectious or inflammatory conditions were ruled out by the demonstration of a dominant clonal population. In situ hybridization showed that the plasma cells are Kappa light chain restricted, while molecular study for IgH gene rearrangement showed a clonal immunoglobulin heavy-chain gene rearrangement.

MALT lymphoma, notably in the lung and gastrointestinal tract, often has a characteristic t(11;18)(q21;q21) translocation. In this translocation, the 3′ end of MALT1 was fused to the 5′ portion of API2, an inhibitor of apoptosis located at 11q21 leading to production of API2-MALT1 fusion transcript \[[@CR22]\]. The frequency of this translocation varies depending on the site of origin of the tumor and it was absent or present at very low frequencies in thyroid, skin, liver, and other rare sites \[[@CR23]\].

Streubel et al. \[[@CR24]\] have identified a second chromosomal aberration involving the MALT1 gene and IgH on 14q32 rather than the API2. Their study showed that 18% (12 out of 66) of the MALT lymphomas were positive for t(14;18)(q32;q21). Interestingly, the anatomical distribution of MALT lymphoma with t(14;18)(q32;q21) was different from that with t(11;18)(q21;q21). The t(14;18) was positive in MALT lymphoma involving ocular adnexa, skin, and the salivary glands, and negative in pulmonary and gastrointestinal MALT lymphoma. MALT lymphomas with different chromosomal abnormalities involving different anatomical sites may indicate different pathogenetic pathways, e.g., the gastric MALT lymphoma is associated with H pylori, whereas those of ocular adnexa, skin, and salivary glands may be associated with other infectious agents or autoimmune diseases.

In the present case, FISH study showed a positive rearrangement of the MALT1 locus. Subsequent studies showed IgH/MALT1 fusion. To our knowledge, this is the first case of primary dural lymphoma of MALT type with a translocation involving IgH and MALT1 genes. The largest series of dural MALT lymphoma reported in the literature was by Tu et al. \[[@CR25]\]. They were able to perform FISH study in 12 of the 15 cases. None of their cases showed t(14;18) or t(11;18) translocations. However, 50% of their cases showed trisomy 3 (six out of 12 cases) while our case was negative for this abnormality. Similarly, Kelly et al. \[[@CR18]\] have also performed FISH study in their case report and the result was negative for t(11;18) and t(14;18). Additional cases of dural MALT lymphoma need to be studied by FISH to determine the precise frequency of MALT1 rearrangement. Our case suggests that MALT1 translocation play a pathogenetic role in some PCNS MALT lymphoma similar to the other extranodal lymphoma.

In conclusion, we report a rare case of primary dural MALT lymphoma with prominent plasmacytic differentiation and the diagnosis was confirmed by a monoclonal IgH gene rearrangement and a positive MALT1 rearrangement involving IgH and MALT1 on chromosome 14 and 18, respectively.
